Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
US biotech has been struggling to overcome fall in demand for coronavirus jabs
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...Many companies across multiple industries seek to become consolidators that create platforms to extract synergies, increasingly funded by private equity....
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
US healthcare company is putting cash to work from spinning off its consumer health arm
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...It is projecting $235mn of “synergies” — mostly cost savings one would hope. Taxed and capitalised, these would be worth about $1.8bn, or more than three times the premium....
US drugmaker is trying to chart its future without blockbuster Covid-19 products
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...HPE says the combination is worth $450mn of annual cost synergies, or nearly a tenth of Juniper’s revenue. The all-cash buyout is transformative for HPE, whose enterprise value is $30bn....
Millions of Paxlovid pills have gone unused as tight controls restrict access
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
Investor worries about the impact of weight loss drugs on food companies are overdone
...They estimated that an all-stock combination of Warner and Paramount could yield at least $1bn of synergies....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
Rare step comes after Brussels fined US biotech for buying Grail without approval
International Edition